436 Trastuzumab- (H) and everolimus- (RAD001) containing regimens are safe and active when reintroduced in patients (pts) with HER2-overexpressing metastatic breast cancer (MBC) pre-treated with lapatinib

MLA

T. Sahmoud, et al. “436 Trastuzumab- (H) and Everolimus- (RAD001) Containing Regimens Are Safe and Active When Reintroduced in Patients (Pts) with HER2-Overexpressing Metastatic Breast Cancer (MBC) Pre-Treated with Lapatinib.” European Journal of Cancer Supplements, vol. 8, Mar. 2010, p. 186. EBSCOhost, https://doi.org/10.1016/s1359-6349(10)70458-4.

APA

T. Sahmoud, L. Vittori, Cristian Massacesi, C. Manlius, Ruth O’Regan, Luca Gianni, F. Andre, Florence Dalenc, Yunyu Zhang, & M. Campone. (2010). 436 Trastuzumab- (H) and everolimus- (RAD001) containing regimens are safe and active when reintroduced in patients (pts) with HER2-overexpressing metastatic breast cancer (MBC) pre-treated with lapatinib. European Journal of Cancer Supplements, 8, 186. https://doi.org/10.1016/s1359-6349(10)70458-4

Chicago

T. Sahmoud, L. Vittori, Cristian Massacesi, C. Manlius, Ruth O’Regan, Luca Gianni, F. Andre, Florence Dalenc, Yunyu Zhang, and M. Campone. 2010. “436 Trastuzumab- (H) and Everolimus- (RAD001) Containing Regimens Are Safe and Active When Reintroduced in Patients (Pts) with HER2-Overexpressing Metastatic Breast Cancer (MBC) Pre-Treated with Lapatinib.” European Journal of Cancer Supplements 8 (March): 186. doi:10.1016/s1359-6349(10)70458-4.